Skip to main navigation Skip to search Skip to main content

A review on DNA vaccines in pre-clinical trials against SARS-CoV-2

  • Dinesh Kumar Lakshmi Narayanan
  • , Sinouvassane Djearamane
  • , Shivkanya Fuloria
  • , Saminathan Kayarohanam
  • , Vetriselvan Subramaniyan
  • , Mahendran Sekar
  • , Neeraj Kumar Fuloria

Research output: Contribution to journalArticleOther

Abstract

COVID 19 Pandemic is caused by the viral pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Scientific fraternity worldwide swiftly developed various types of vaccines for the prevention and as mitigation measures for curbing the pandemic. Traditional inactivated vaccines, mRNA vaccines (protein subunits such as spike proteins), and viral vector vaccines (non-replicating vectors with protein subunits) have been approved by World Health Organisation (WHO) for emergency use. The emergence of many mutated variants has been a worrying factor in the fight against the pandemic. There has been continuous research in the quest for more therapeutics, especially vaccines to curb and stop the pandemic. According to WHO, there are 194 vaccines in pre-clinical trials belonging to various types out of which sixteen is DNA vaccines. In this review, we have discussed the advantages and disadvantages of the DNA vaccines for Covid-19. This article tried to explore the available information on DNA vaccines and their current status against Covid – 19 which are in pre-clinical trials.

Original languageEnglish
Pages (from-to)487-493
Number of pages7
JournalJournal of Experimental Biology and Agricultural Sciences
Volume10
Issue number3
DOIs
Publication statusPublished - 26 Jun 2022
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Clinical trials
  • Covid-19
  • DNA vaccines
  • Vaccines

Cite this